Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 31, 2013

View Archived Issues

Recombinant VWF-A2 polypeptide shows promise in LPS-induced DIC mouse model

Limited efficacy seen for ganetespib in patients with HCC

Peptide drug shows promise for skeletal dysplasia diseases related to FGFR3 gene mutations

Abbott updates recent pipeline progress

Amgen offers overview of fourth quarter 2012

Gilead Sciences presents novel voltage-gated sodium channel blockers

Sanofi presents new wound-healing agents

Bayer scientists patent new ALK-1 and SMAD 7 inhibitors

Model of hyperoxic injury shows adaptive changes against infection and ROS

Merck Serono and Feinstein Institute enter partnership

Galapagos receives grant for IBD research

Huabo Biopharm divulges novel bifunctional fusion proteins

The Technische Universitat Dresden patents novel antibodies for cancer

Gene-gene interactions associated with colorectal cancer risk identified

Vaxart begins phase I study of adjuvanted adenoviral-based influenza vaccine

Endocyte set to advance EC-1069 development

Adventrx begins pivotal phase III study of ANX-188

Medgenics begins phase I/II trial of Infradure tissue treatment in hepatitis C

Mesoblast cleared to begin study of mesenchymal precursor cells in patients with RA

Organovo and OHSU Knight Cancer Institute collaborate on in vitro cancer models

New collaboration on serological peptide markers for diagnosis of CFS

French ANSM to suspend marketing of Diane-35 and generics for acne

Dilaforette gains clearance in India to conduct phase II study of severe malaria treatment

Diamyd Medical to conduct new study of diabetes vaccine

Phase III ovarian cancer study of Opaxio continues following interim analysis

Encouraging results from phase III study of obinutuzumab in CLL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...